Phase 1 N=81 Safety of Single Rising Doses and Relative Bioavailability of BI 691751
Healthy
Primary: AUC0-72h (Part II) — 2740; 3050; 2800 nmol*h/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=36 Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
Posttraumatic Stress Disorder
Primary: PTSD Severity — 23.8; 34.6 units on a scale — p=0.17
Phase 3 N=643 A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Died During the Overall Study — 73.2; 75.2 percentage of participants
Phase 2 N=72 Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome (MDS)
Primary: Percentage of Participants With a Hematologic Response Based on the International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS) and Programmatically…
Phase 3 N=673 A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
Anemia
Primary: Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period — -0.10; 0.01; -0.10 gram per deciliter (g/dL) — p=<0.0001
N/A N=163 New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)
Alzheimer Disease · Behavioral Disorders · Cognitive Impairment
Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1
Phase 2 N=31 Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Adult Anaplastic Astrocytoma · Adult Diffuse Astrocytoma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients
N/A N=10,003 PROspective Multicenter Imaging Study for Evaluation of Chest Pain
Chest Pain
Primary: Time to Primary Endpoint — 1.0; 1.1; 1.2; 1.4 Percentage of participants with an event
Phase 2 N=44 Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Incidence of Durable Stable Disease, Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 18 particip[ants
Phase 3 N=582 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
Non-Squamous Cell Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint — 12.19; 9.36 Months — p=0.0015
Phase 3 N=120 An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne
Acne
Primary: Reduction of Undesirable Effects — 26; 38; 35; 10 participants — p=0.001
Phase 2 N=17 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Grade 3-4 Acute GVHD Rate — 29.4 percentage of participants
Phase 2 N=40 Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Primary: Percentage of Participants Who Received Treatment Including Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events (AEs) — 62.5 Percentage of…
Phase 2 N=122 Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Disease-free (DFS) or Relapse-free Survival (RFS) Time — 15.9 Months
Phase 4 N=20 Desensitization in Kidney Transplantation
HLA Sensitization
Primary: Number of Living Donor Transplant Candidates That Are Transplanted — 19 participants